Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis.
Two cases are reported of patients who developed agranulocytosis after treatment with typical and atypical antipsychotics. The patients were successfully treated with olanzapine. We suggest the consideration of olanzapine as a safer treatment in patients who require immediate continuation of antipsychotic medication and have a prior history of classic and atypical neuroleptic-induced agranulocytosis.
Lev Hasharon Mental Health Medical Center, Netanya, Israel.
B
B
Finkel
A
A
Lerner
I
I
Oyffe
D
D
Rudinski
M
M
Sigal
A
A
Weizman
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines; D003006:Clopenthixol / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003006:Clopenthixol; D018967:Risperidone; D000077152:Olanzapine